On March 6, 2018 Molecular Partners AG (ticker: MOLN), a clinical-stage biopharmaceutical company developing a new class of drugs known as DARPin therapies*, reported that it will present at the Cowen and Company 38th Annual Healthcare Conference on Tuesday, March 13, 2018 at 8:00 ET (2:00 PM CET) (Press release, Molecular Partners, MAR 6, 2018, View Source [SID1234524455]).

Schedule your 30 min Free 1stOncology Demo!
Discover why more than 1,500 members use 1stOncology™ to excel in:

Early/Late Stage Pipeline Development - Target Scouting - Clinical Biomarkers - Indication Selection & Expansion - BD&L Contacts - Conference Reports - Combinatorial Drug Settings - Companion Diagnostics - Drug Repositioning - First-in-class Analysis - Competitive Analysis - Deals & Licensing

                  Schedule Your 30 min Free Demo!

The presentation, followed by a breakout session, will be hosted by Dr. Patrick Amstutz, CEO of Molecular Partners and Dr. Michael Stumpp, CSO of the company.

The presentation will be webcast live and can be accessed on the day via this link. A copy of the presentation handout as well as a replay of the webcast will be made available on the company’s website www.molecularpartners.com under the Investors section. The replay will be available for 90 days following the presentation.